Acuvail®
Ketorolac 0.45% · ophthalmic solution
NSAID
Approved uses
Pain and inflammation following cataract surgery
One drop BID to the affected eye starting 1 day before surgery, on the day of surgery, and through the first 2 weeks postoperatively.
Median time to pain resolution is 1 day, with most patients pain free by postoperative day 1.
Contraindications
Previously demonstrated hypersensitivity to any of the ingredients in the formulation
0.45% (4.5 mg/mL) preservative-free solution, 0.4 mL single-dose vials, carton of 30 vials in 3 pouches of 10
Nonsteroidal anti-inflammatory drug of the pyrrolo-pyrrole group. When administered systemically, it has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. Its mechanism of action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Warnings & Precautions
- Delayed healing: Topical NSAIDs may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
- Cross-sensitivity or hypersensitivity: There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. There have been reports of bronchospasm or exacerbation of asthma in patients with a known hypersensitivity to aspirin/NSAIDs or a past medical history of asthma. Use caution in individuals who have previously exhibited sensitivities to these drugs.
- Increased bleeding time: With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
- Corneal effects: Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, which may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use and be closely monitored for corneal health.
- Increased risk for corneal adverse events: Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Use topical NSAIDs with caution in these patients.
- Occurrence and severity of corneal adverse events: Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
- Contact lens wear: Not to be administered while wearing contact lenses.
- Risk of contamination: Avoid allowing the tip of the single-dose vial to contact the eye or surrounding structures, because the tip could become contaminated by common bacteria known to cause ocular infections, or the eye could be injured. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Common Side Effects
The most common adverse reactions, reported in 1% to 6% of patients, were increased intraocular pressure, conjunctival hyperemia and/or hemorrhage, corneal edema, ocular pain, headache, tearing and vision blurred; some of these may be the consequence of the cataract surgical procedure. Allergic reactions, including eye swelling, hyperemia, and pruritis, have also occurred during treatment with ketorolac tromethamine ophthalmic solutions. Postmarketing reports include corneal erosion, corneal perforation, corneal thinning and corneal melt, epithelial breakdown, ulcerative keratitis, bronchospasm, and exacerbation of asthma.
Pregnancy: No adequate and well-controlled studies in pregnant women; no teratogenicity seen in rats or rabbits at clinically relevant doses.
Lactation: Presence in human milk after topical dosing is unknown; use caution in a nursing woman.
Safety and effectiveness not established below age 2.